M
ultidrug-resistant tuberculosis (MDR-TB), defined as resistance to isoniazid and rifampin, occurred in an estimated 440,000 individuals worldwide in 2008 (28) . Cure rates are dismal compared to drug-susceptible tuberculosis (12) . Determination of appropriate therapy requires knowledge of the drug resistance profile of the organism. Molecular assays for common resistance mutations to isoniazid and rifampin are of great value, yet once these have been identified, the challenge arises of identifying a regimen of several medications to which the Mycobacterium tuberculosis isolate is susceptible. The standard drug susceptibility method is culture based, either on solid or liquid medium (1, 29) , and completion takes weeks to months, during which time the patient may be suboptimally treated. Genotypic assays that detect mutations that confer resistance to injectable and fluoroquinolone antibiotics are emerging, such as assays for gyrA for fluoroquinolones and rrs and eis for injectables. However, sensitivity and specificity of these mutations appear to reside in the 80 to 90% range, and interpretation of these mutations is complex and best made with precise sequencing results (8) . For other drugs, such as paraaminosalicylic acid, cycloserine, ethionamide, and linezolid, genotypic testing does not exist. Therefore, more rapid methods of phenotypic drug susceptibility testing are greatly needed.
For these reasons, we have developed a rapid phenotypic drug susceptibility method that could be used with any drug. We recently published a quantitative PCR (qPCR)-based method (24) that utilized amplification of the M. tuberculosis 16S rRNA gene after 3 days of incubation with antituberculous drugs. The assay required use of propidium monoazide, a DNA-binding dye to decrease background amplification from killed organisms. It entailed several steps, including exposure to bright light and a wash that required strict biosafety. In this work, we sought to speed and simplify a qPCR-based assay by utilization of mycobacteriophage.
For many years, bacteriophages have been used as research tools to enhance understanding of microbial pathogens. Recently, they have been applied in bacterial detection assays to rapidly detect the presence of viable bacterial cells (19) . D29 mycobacteriophage has been shown to successfully infect and detect the presence of viable M. tuberculosis cells (19, 22) . The bacteriophage is specific to mycobacterium through recognition of host surface proteins from which it infects. D29 mycobacteriophage is advantageous in detecting slow-growing mycobacteria because it invades the host cell in seconds and begins DNA replication within minutes (5, 27) . Studies with Mycobacterium smegmatis have shown release of D29 progeny phage as early as 90 min after infection (9, 22) .
Several mycobacteriophage-based assays have been attempted for both detection and drug susceptibility testing of TB. Two main approaches have been used: detection of progeny phages using sensor cells such as M. smegmatis (21) and detection of reporter constructs generated by engineered phages, such as luciferaseproducing phages (3, 4, 14, 21) . Certain phage-based assays have been commercialized, such as FASTPlaqueTB (17) , which uses D29 phage for detection of M. tuberculosis directly from sputum, and FastPlaque-Response, which detects rifampin resistance (15) . Readout of these assays entails lawns of sensor cells. Luciferase reporter mycobacteriophages have yielded promising drug susceptibility test (DST) data for isoniazid, rifampin, streptomycin, and ethambutol with a median turnaround time of 3 days (2); however, the assay requires manipulating liquid cultures of TB in a luminometer, which is not widely available; thus, other engineered phage constructs are being tried (26) . Finally, these phagebased approaches have reported only qualitative susceptible/resistant results.
We therefore sought to improve upon these phage-based methods by developing a real-time PCR assay of phage DNA that could work on any of the 13 main antituberculous drugs without the need of sensor cells or engineered phages. Real-time PCR is increasingly available to clinical laboratories worldwide. We also sought to quantitate the real-time PCR cycle threshold as a maneuver to estimate the MIC of the organism.
MATERIALS AND METHODS
Mycobacterial strains and culture conditions. Mycobacterial strains used in this study included M. smegmatis (ATCC 607), M. tuberculosis H37Rv (ATCC 27294), and 32 clinical isolates confirmed as M. tuberculosis complex by a sequence-specific FRET probe (11) . These included 9 susceptible strains, 22 multidrug-resistant (MDR) TB strain, and 1 XDR TB strain obtained from the Mycobacteriology Service Unit, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. All work was approved by the University of Virginia Institutional Biosafety Committee and Human Investigation Committees. TB isolates were cultured on Lowenstein-Jensen medium at 35°C for 3 weeks. Cell suspensions were prepared in Middlebrook 7H9 (M7H9) broth supplemented with Middlebrook oleic acid-albumin-dextrosecatalase (OADC) enrichment (Difco, Livonia, MI) and adjusted to a 0. Antimicrobial agents. Drugs used were isoniazid (INH), rifampin (RIF), streptomycin sulfate (STR), kanamycin sulfate (KAN), ofloxacin (OFX), ethionamide (ETH), para-aminosalicylic acid (PAS), and Dcycloserine (CS; all from Sigma-Aldrich, St. Louis, MO); ethambutol hydrochloride (EMB), amikacin (AMK), capreomycin sulfate (CAP; all from MP Biomedicals, Solon, OH); moxifloxacin (MXF; 400 mg/250 ml in NaCl injection form) and linezolid (LZD; 600 mg/300 ml in water injection form) (both from University of Virginia Pharmacy, Charlottesville, VA). INH, EMB, AMK, KAN, STR, CAP, and CS were dissolved in sterile distilled water. RIF and ETH were dissolved in dimethyl sulfoxide. OFX was dissolved in 0.1 N NaOH, and PAS was dissolved in ethanol. All stock solutions were stored in single-use aliquots at Ϫ80°C.
Standard agar proportion method. Antimicrobial susceptibility tests were carried out in Middlebrook 7H10 agar (Difco) according to standard procedures (20) . Briefly, a 1.0 McFarland standard suspension was diluted 10-fold serially in sterile distilled water, and dilutions of 10 Ϫ2 and 10
Ϫ4
were inoculated onto M7H10 with and without drug and incubated at 35°C. Where available, critical concentrations endorsed by WHO (29) were used. Results were read 21 days after the inoculation of media. At the critical concentration of each drug, bacterial growth was counted and calculated for the percentage of resistant colonies, whereby Ն1% is defined as resistance. H37Rv, susceptible to all drugs tested, was used for quality control. Sequencing of loci. DNA was isolated from 2 weeks of TB culture. Briefly, 1 ml of 1.0 McFarland standard suspension was transferred to a 2-ml screw-cap tube and centrifuged at 21,000 ϫ g for 15 min; the pellet was resuspended in 500 l Tris-EDTA (TE) buffer, boiled at 100°C for 30 min, and centrifuged at 21,000 ϫ g for 5 min; and supernatants were stored at Ϫ20°C for the template. Seven loci were amplified by PCR-rpoB (RIF), katG and inhA (INH), embB (EMB), gyrA (OFX, MXF), rrs (KAN, CAP, and AMK), and eis (KAN)-using the locus-specific primers of Campbell et al. (8) . Each 25-l PCR mixture contained 12.5 l HotStarTaq master mix (Qiagen), 0.15 l of the forward and reverse 50 M primers, 7.2 l nuclease-free water, and 5 l of genomic DNA. PCR was performed on an MyCycler (Bio-Rad, Hercules, CA) and included an initial denaturation step at 95°C for 15 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 30 s, with a final elongation step at 72°C for 7 min. PCR products were analyzed on 2% agarose gels, and verified PCR products were purified using the MinElute PCR purification kit (Qiagen) by following the manufacturer's protocol. Purified PCR products were measured spectrophotometrically, diluted with nuclease-free water, mixed with primers, and then submitted to GeneWiz (South Plainfield, NJ) for DNA sequencing.
Trek Sensititre MYCOTB assays. The MIC were determined using the Sensititre MYCOTB kit (TREK Diagnostic Systems, West Sussex, United Kingdom) according to the manufacturer's procedure. Briefly, 100 l of 0.5 McFarland standard TB suspensions was transferred into a tube of 10 ml 7H9 broth supplemented with OADC to yield inoculums of 1 ϫ 10 5 CFU/ml, 100 l was transferred into each well of a 96-well plate coated with and without several concentrations of each drug, and all wells were covered with an adhesive seal and incubated aerobically at 35°C for 10 days. Per the manufacturer's instructions, growth was evaluated visually at 10 days, and if positive-control growth was not apparent, then the incubation was extended to 21 days. The MIC was recorded as the lowest antibiotic concentration that reduced visible growth.
Propagation and quantification of the D29 phage. The D29 phage (Biotec Laboratories Ltd., Ipswich, United Kingdom) was propagated by following the standard protocol (18) . Briefly, 10% volume of stationaryphase M. smegmatis was added to M7H10 and 10% OADC and poured into a petri dish, and 100 l of approximately 4 ϫ 10 3 PFU/ml D29 phage was spread. Plates were incubated at 35°C overnight, and 10 ml M7H9 with 10% OADC and 4 mM CaCl 2 was added and reincubated. Broth was removed and filtered through sterile 0.45-m filters, aliquoted, and stored at 4°C. For quantification, serial dilutions were made, and 10 l of phage was mixed with 200 l M. smegmatis and 4 ml melted M7H10 agar, poured onto M7H10 plates, and incubated at 35°C for 24 to 48 h. Visible plaques were counted.
Optimization of D29 phage assay conditions. H37Rv was used to optimize conditions. For antimicrobial killing, TB strains were diluted in M7H9, 10% OADC, and 4 mM CaCl 2 with drug at critical concentrations and incubated at 35°C for 3 days. D29 phage was added into live and drug-treated TB followed by phage incubation at 35°C, DNA extraction, and qPCR. The optimal phage concentration and phage incubation duration was varied as indicated. For TB CFU counts, serial dilutions were made and 10 l was dropped on M7H10 agar and incubated at 35°C for 3 weeks. Plaque counts were performed as described above.
Evaluation of optimized D29 phage assay. A total of 33 isolates of M. tuberculosis were tested for drug susceptibility using the D29 phage assay. Thirteen drugs-INH, RIF, EMB, STR, AMK, KAN, CAP, OFX, MXF, LZD, ETH, PAS, and CS-were prepared using recommended critical concentrations for MGIT960 broth media (29) with 10% OADC and 4 mM CaCl 2 . For RIF, STR, AMK, KAN, CAP, OFX, MXF, LZD, and CS, 90 l of each drug was transferred to a 96-well PCR plate, and 0.5 McFarland standard TB suspensions were diluted 1:10 in M7H9 with 10% OADC and 4 mM CaCl 2 to yield inocula of 1 ϫ 10 6 CFU/ml. Ten microliters of TB suspensions was added into each well followed by 10 l of D29 phage (1 ϫ 10 4 PFU/ml) and incubated at 35°C for 24 h. For INH, EMB, ETH, and PAS, TB cells were incubated with drug at 35°C for 48 h prior to adding D29 phage, followed by incubation at 35°C for 24 h. D29 phage qPCR assay. D29 phage-infected cells were incubated in a heating block at 100°C for 30 min and then centrifuged at 8,000 ϫ g for 5 min, with supernatant used as the DNA template. The primers D29-F (5=-AGCCGATCAGAAGCACGGGC-3=) and D29-R (5=-AGCGGCTCT TAGGAGGGGCC-3=) were designed to amplify a 225-bp untranslated region within the D29 phage genome. These primers did not amplify M. tuberculosis DNA alone. PCR mixtures (25 l) consisted of 12.5 l of 2ϫ iQSYBR green supermix (Bio-
Statistical analysis. Means were compared using t test or MannWhitney test. All TB cultures were performed in duplicate. Data are shown as means or means Ϯ standard deviations (SD). The correlation between C T values (⌬C T ) and MICs was calculated by Pearson correlation. Receiver-operating characteristic (ROC) analysis was performed with PASW Statistics Software and was used to define a cutoff in the ⌬C T values that compared to agar proportion results. All P values were two-tailed.
RESULTS
Development of D29 phage-qPCR assay. The hypothesis of our assay was that phage would infect and replicate their doublestranded DNA in viable TB cells and that this DNA could be quantified by real-time PCR to discern TB viability in the setting of drug treatment. To first examine this, we performed qPCR for phage alone versus phage added to TB grown in control media (Fig. 1A) . A total of 1,000 PFU/ml of D29 mycobacteriophage and 10 5 CFU/ml of TB that were previously grown in control media for 72 h were used. Both H37 Rv and a clinical MDR strain (INH, RIF, EMB, STR resistant) were assayed, and as expected in both instances there was a marked decrease in the real-time PCR cycle threshold (C T ) values reflective of increased quantities of phage DNA. Furthermore, upon INH or RIF pretreatment of H37Rv, the number of phage did not increase and the C T value did not decrease. In contrast, the phage number increased and the C T value decreased when an MDR-TB strain was pretreated with INH or RIF. We then sought to optimize the parameters of the assay. Durations of phage incubation were compared, and this revealed that 24 h of phage incubation was superior to 6 h of phage incubation as measured by a larger ⌬C T (TB-phage Ϫ phage alone) when using H37Rv grown in control medium for 72 h (Fig. 1B) . We then sought to examine the optimal phage inoculum for the assay and observed 10 3 offered the largest ⌬C T (TB-phage Ϫ phage alone) versus 10 4 or 10 5 phage (Fig. 1C) . The diminished ⌬C T when 10 4 or 10 5 phage was used was due to elevated background/reduced C T in the phage-alone wells without commensurate reduction in C T in the TB-phage wells (data not shown). We then compared durations of TB incubation. For both H37Rv and MDR TB, we observed that the phage C T values decreased progressively with 24, 48, and 72 h of growth (Fig.  1D) . As expected, this corresponded to increased numbers of M. tuberculosis CFU/ml. Likewise the phage C T values corre- CFU/ml), and phage plus TB pretreated with drugs for 72 h were compared. All samples were boiled and subjected to qPCR for phage DNA. Raw data are shown. (B) Durations of 6 and 24 h of phage incubation with 72-h-drugtreated H37Rv were compared; (C) phage concentration was evaluated by comparing 10 3 , 10 4 , and 10 5 PFU/ml of phage added to 72-h-treated H37Rv and MDR-TB, followed by 24 h of phage incubation; (D) duration of drug treatment was evaluated by comparing 24 h, 48 h, and 72 h of drug treatment of H37Rv and MDR-TB prior to 24 h of 10 3 phage incubation. Phage qPCR C T , plaque counts, and TB CFU were evaluated. Real-time PCR C T was compared to D29 phage plaque counts and bacterial colony counts as a function of drugtreated time over 1 to 3 days followed by 24 h of phage incubation. (E) Durations of drug pretreatment prior to phage versus drug cotreatment with phage were compared as indicated. Experiments shown in panels B, C, and E were performed in duplicate, and data are shown as mean ⌬C T (C T TB-phage Ϫ phage alone). *, P Ͻ 0.05; NS, P values not statistically significant. lated with numbers of phage as quantified by conventional plaque counts on M. smegmatis indicator plates. For H37Rv, the qPCR C T became clearly disparate with 24 h of rifampin treatment. In contrast, 48 h of INH treatment was required for a similar ⌬C T (C T control Ϫ C T INH). We then more closely examined the durations required for pretreatment of TB with drugs prior to phage incubation, and the capacity for cotreatment of TB with drugs and phage from the outset (Fig. 1E) . This confirmed that INH pretreatment was required and that 48 h was superior to 24 h, 6 h, and 3 h as measured by ⌬ C T (C T control Ϫ C T INH). In contrast, while 48 h of RIF pretreatment was clearly able to discern drug susceptibility, so was 24 h, 6 h, Evaluation of D29 phage qPCR assay on clinical isolates. After the assay was developed with H37Rv and an MDR strain using RIF and INH, we then examined its performance on all major antituberculous medications in current use. We observed that the performance with EMB, ETH, and PAS as similar to that with INH, in that 48 h of drug treatment of TB prior to 24 h of phage incubation yielded an optimal ⌬C T in strains confirmed as drug susceptible by the agar proportion method. In contrast, STR, AMK, KAN, CAP, OFX, MXF, LZD, and CS behaved in a manner similar to that of RIF in that no pretreatment was required. Therefore, drug, TB inoculum, and phage could be added simultaneously and yield a disparate statistically significant ⌬C T in 24 h. For these drugs 48 h of drug pretreatment, akin to the INH method, also yielded a clearly disparate ⌬C T , but we pursued the rapid 24-h method in this work. In sum, we applied the following conditions for 33 TB strains: (i) 48-h drug treatment followed by 24 h of 10 3 PFU/ml phage incubation for INH, EMB, ETH, and PAS and (ii) simultaneous drug and 10 3 PFU/ml phage incubation with TB for 24 h for RIF, STR, AMK, KAN, CAP, OFX, MXF, LZD, and CS. For these 33 strains, we also scaled down the volume of the phage assay from 500 l in tubes to 100 l in a 96-well PCR plate. All 33 strains were tested using the standard agar proportion method with the critical concentration for each drug as shown in Table 1 , where resistance is defined as Ն1% growth of colonies on drugcontaining media (29) . All strains were also characterized genotypically at the rpoB, inhA, katG, embB, gyrA, rrs, and eis loci (see Table S1 in the supplemental material). The ⌬C T (C T control Ϫ C T drug) was determined and compared to the conventional agar proportion results (Fig. 2 and 3 ). We noted a significantly lower average ⌬C T among susceptible strains than among resistant strains for all 13 drugs (P Ͻ 0.05). We assigned a ⌬C T cutoff of ϩ0.3 to Ϫ6.0 for each drug using ROC analysis (Table 2) , and these yielded accuracies of 100% for all drugs except capreomycin (97%) and ethionamide (82%). This reflected 1 false resistant capreomycin result very near the cutoff, 4 false resistant ethionamide results, and 2 false susceptible ethionamide results. We had few resistant isolates for linezolid, cycloserine, amikacin, capreomycin, ofloxacin, and moxifloxacin; thus the cutoffs are not certain for these drugs.
Relationship of D29 phage qPCR and MIC values. MICs for TB isolates are very rarely pursued because they are time and re- 
FIG 2
Correlation between D29 phage qPCR results and the standard agar proportion method using the cotreatment method. Thirty three M. tuberculosis isolates were tested by phage qPCR and agar proportion assay for susceptibility to rifampin, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, linezolid, and cycloserine. For the phage qPCR assay, TB isolates were coincubated with drugs or control media and phage for 24 h prior to boiling and qPCR. All phage assays were performed in duplicate, and mean qPCR C T is shown. Cutoff threshold values were determined by ROC analysis. The red Ϫ symbols indicate standard assay results that were discrepant with D29 phage qPCR.
FIG 3
Correlation between D29 phage qPCR results and the standard agar proportion method using the pretreatment method. Thirty three M. tuberculosis isolates were tested by phage qPCR and agar proportion assay for susceptibility to isoniazid, ethambutol, ethionamide, and para-aminosalicylic acid. For the phage qPCR assay, TB isolates were pretreated with drugs or control media for 48 h, followed by phage incubation for 24 h, and then boiling and qPCR. All phage assays were performed in duplicate, and mean qPCR C T is shown. Cutoff threshold values were determined by ROC analysis. The red ϫ and Ϫ symbols indicate standard assay results that were discrepant with D29 phage qPCR.
source intensive. We hypothesized that the quantitative ⌬C T value might correlate with the MIC of the isolates: specifically, the greater the ⌬C T between control and drug-treated cells, the more susceptible the isolate should be to the drug. 
DISCUSSION
In this work, we have developed a rapid 1-to 3-day phenotypic drug susceptibility test for TB. The test provides results that are accurate compared to the agar proportion method for the 13 main antituberculous drugs and can permit one to construct an appropriate MDR or XDR TB regimen rapidly. The resulting assay is faster, easier to use, more biosafe, and equally or more accurate than our recent propidium monoazide (PMA) qPCR approach (24) . Indeed, for RIF, STR, AMK, KAN, CAP, OFX, MXF, LZD, and CS, we were able to obtain results in 1 day by cotreating TB with drug and phage for 24 h, followed by boiling and PCR. For the laboratory, this means that if the wells are set up in a 96-well PCR plate, the plate can be sealed, placed in the incubator, and then boiled in a heatblock, rendering it biosafe.
In contrast, as is the typical protocol for most phage-based DST methods, INH, EMB, ETH, and PAS required 48 h of pretreatment with drug prior to phage incubation. Presumably, the differences among drugs in their ability to affect phage replication relate to their mechanisms of action. Since phage replication requires intact DNA, RNA, and protein synthesis machinery within the host cell, it is not surprising that fluoroquinolones (inhibit DNA synthesis), RIF (inhibits RNA polymerase [7] ), and aminoglycoside injectables and LZD (inhibit protein synthesis) are able to quickly prevent phage DNA replication in our system. In contrast, INH, EMB (10), ETH, and to some extent PAS (which is also a folate antagonist [25] ) are cell wall synthesis inhibitors, and we suspect inhibition of these mechanisms takes time for cell injury, during which phage replication can occur, hence the requirement for 48 h of pretreatment. We are less able to explain the rapid activity of CS, whose mechanism of action is not clear but also appears to involve cell wall synthesis (6) . We would emphasize that if one wishes to test all drugs with the 48-h pretreatment approach, the ⌬C T separation for RIF, STR, AMK, KAN, CAP, OFX, MXF, LZD, and CS is even better than with the 24-h method (data not shown). At times, we observed differences in ⌬C T of strains from experiment to experiment (e.g., H37Rv pretreated with 72 h of RIF yielded a ⌬C T of approximately Ϫ5 in Fig. 1B versus Ϫ11 in Fig. 1D ), which we presume relates to the growth state of the control TB. However, this is a factor with any phenotypic DST, and the assay remained highly reproducible in our hands, with tight standard deviations in the ⌬C T results (Fig. 4) . Importantly, there were only seven (7/429 ϭ 1.6%) instances where the D29 phage qPCR assay was discrepant with the conventional methods. These were due to a capreomycin result near the cutoff and 6 discrepancies for ethionamide, a drug where DST methods are known to be imperfect (16, 23) .
The protocol is amenable to high throughput given the microplate format and can be performed by any laboratory currently performing culture-based DST that has access to a real-time PCR thermocycler. We hope this assay can be tested in other settings to refine the ⌬C T cutoffs and examine additional isolates. The isolates used in these experiments were generally of high-level resistance, and thus the performance across a range of MICs needs to be further evaluated. Due to relatively few isolates resistant to moxifloxacin and other second-line drugs, and none for linezolid and cycloserine, evaluation of the assay for these types of resistant strains was limited. In the future, we aim to evaluate the performance of the assay on a larger variety of resistant isolates and adapt the assay for direct specimens. Finally, the ⌬C T value correlated with the MIC for most drugs. The role of MICs in the management of TB is not yet defined, but we speculate it will find use in treating MDR and XDR TB where drug options are limited. Even in Virginia, we have noted that the majority of TB patients who are responding slowly to 4-drug therapy have 2-hour serum levels below the expected range and often below the critical concentration for INH or RIF (13) . In this context, knowing the MIC of the organism may become clinically relevant, and we feel this ⌬C T quantitative metric is the strength of this assay. 
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